Valeant to sell iNova Pharmaceuticals for £930 million

By Romily Broad
Valeant Pharmaceuticals has agreed sell its iNova Pharmaceuticals business for $930 million in cash. It will be sold to a company jointly owned by Paci...

Valeant Pharmaceuticals has agreed sell its iNova Pharmaceuticals business for $930 million in cash.

It will be sold to a company jointly owned by Pacific Equity Partners and The Carlyle Group, and the announcement saw shares in the Canadian drugmaker bounce almost 5% in premarket trading to reach $12.60.

The sale is part of a continuing effort by new CEO Joseph Papa to tackle the company's huge long-term debts, recorded at $28.5 billion in March 2017. The debt had been piled up in an acquisition spree led by former CEO Mike Pearson. It was a spree that saw the company's share price rise as high as $257 in 2015, before nosediving in the wake of controversies over its pricing strategy and an association with a speciality pharmacy.

"The sale of iNova is part of the company's ongoing efforts to both simplify our operating model and strengthen our balance sheet," said Papa in a statement.

"We will continue to evaluate opportunities that will enable us to deliver on our commitments and unlock value for shareholders."

iNova markets a range of prescription and over-the-counter products in more than 15 countries, including weight management, pain management, cardiology and cough and cold.

Valeant will maintain a presence in these countries primarily through its Bausch + Lomb contact-lens brand, the company says, although it is reportedly considering the sale of part of this business, too.

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare